Every Form 4 that Akebia Therapeutics, Inc. (AKBA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AKBA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKBA filings page.
Akebia Therapeutics, Inc. CEO and President John P. Butler reported exercising stock options for 350,000 shares of common stock on August 6, 2026 at an exercise price of $0.63 per share. The derivative option position was reduced by 350,000 shares, leaving 525,000 options outstanding after the transaction. Following the exercise, Butler directly held 3,718,564 shares of common stock and indirectly held 159,928 shares through the Dorothy Butler Revocable Trust. The options were granted on January 31, 2023 and vest over four years, with 25% vested on January 31, 2024 and the remaining 75% vesting in equal quarterly installments thereafter.
Akebia Therapeutics, Inc. SVP, CFO, CBO & Treasurer Erik Ostrowski reported an open-market sale of 56,019 shares of common stock at $1.11 per share on June 29, 2026. According to the footnote, this was an automatic “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units granted on June 28, 2024, executed under durable instructions adopted on September 8, 2025. After the sale, he directly holds 616,616 shares of Akebia common stock.
Akebia Therapeutics director Myles Wolf received equity awards as part of non-employee director compensation. He was granted 35,700 shares of Common Stock in the form of restricted stock units and a stock option for 53,600 shares at an exercise price of $1.02 per share. Both the RSUs and the option vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant, if that occurs sooner, subject to his continued service. Following the award, he directly owns 169,081 Common Shares and holds the newly granted option for 53,600 underlying shares.
Akebia Therapeutics director Cynthia Smith received new equity awards as part of non-employee director compensation. She was granted 35,700 restricted stock units and an option for 53,600 shares of common stock at an exercise price of $1.02 per share. Both awards vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving. After the RSU grant, she directly holds 196,633 common shares.
Akebia Therapeutics, Inc. reported that director Michael W. Rogers received new equity awards. He acquired 35,700 shares of common stock in the form of restricted stock units granted at no cash cost and not yet vested. He also received a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share. Both the RSUs and the option vest in full on the first anniversary of the June 17, 2026 grant date, or immediately before the first annual stockholder meeting after that date, if earlier, subject to his continuous service. Following these awards, he directly holds 197,429 shares of common stock and 53,600 stock options.
Akebia Therapeutics director Ron Frieson received equity awards as part of his director compensation. He was granted 35,700 restricted stock units under the 2023 Stock Incentive Plan, increasing his direct common stock holdings to 165,200 shares. He was also granted stock options for 53,600 shares at an exercise price of $1.02 per share.
Both the RSUs and the stock options vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholders’ meeting after that date, if he continues serving the company through vesting.
Akebia Therapeutics director Leanne M. Zumwalt received equity awards in the form of common stock and stock options. She was granted 35,700 shares of Common Stock as restricted stock units under Akebia’s 2023 Stock Incentive Plan, bringing her direct common stock holdings to 145,100 shares after the grant.
She was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the RSUs and the option vest 100% on the first anniversary of the grant date, or earlier immediately before the first annual meeting of stockholders after the grant, if she continues serving the company.
Akebia Therapeutics, Inc. director Adrian Adams reported awards of equity-based compensation. He received 35,700 shares of common stock as restricted stock units that were granted at no cash price and increase his direct holdings to 236,200 common shares after the award.
Adams was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the restricted stock units and the stock option are scheduled to vest in full on the first anniversary of the grant date, or earlier immediately before the first annual stockholder meeting after the grant, subject to his continuous service to the company.
Akebia Therapeutics director Philip J. Vickers received a grant of stock options covering 214,400 shares of common stock. The options have an exercise price of $1.41 per share and expire on April 1, 2036. This is a compensation award, not an open-market purchase.
According to the company’s 2023 Plan and its Fifth Amended and Restated Non-Employee Director Compensation Program, one third of the options will vest on the first anniversary of the grant date. The remaining two thirds will vest in equal installments on the first day of each calendar quarter thereafter, if he continues serving the company.
Akebia Therapeutics CEO and President John P. Butler reported an open‑market purchase of 69,270 shares of common stock on March 4, 2026 at an average price of $1.25 per share, with individual trades between $1.23 and $1.28. Following this transaction, his directly held stake rose to 3,367,064 shares of common stock. The filing also notes 159,928 shares held indirectly through the Dorothy Butler Revocable Trust November 20, 2007. A footnote explains that this purchase was matchable under Section 16(b) against a prior sale of 341,305 shares at $1.39 on February 2, 2026, and Butler paid $9,664.60 to Akebia, representing the full short‑swing profit.
Akebia Therapeutics SVP and Chief Accounting Officer Richard C. Malabre reported two stock sales of Akebia Therapeutics, Inc. common shares. On February 2, 2026, he sold 36,142 shares at $1.39 per share and 13,382 shares at $1.39 per share.
The transactions were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025, and were made automatically by the company to cover tax withholding obligations related to vesting of restricted stock units granted on January 31, 2024 and January 31, 2025. After these transactions, Malabre directly owned 299,390 common shares of Akebia.
Akebia Therapeutics chief commercial officer Nicholas Grund reported sales of company stock. On February 2, 2026, he sold 53,585 shares of Akebia common stock at $1.39 per share, followed by an additional sale of 31,244 shares at the same price.
According to the footnotes, one sale was made under a pre-arranged Rule 10b5-1 trading plan, and other sales were made automatically by Akebia to cover tax withholding tied to the vesting and settlement of restricted stock units granted in January 2024 and January 2025. After these transactions, Grund directly owned 561,750 shares of Akebia common stock.
Akebia Therapeutics SVP and Chief Medical Officer Steven K. Burke reported routine share sales tied to equity compensation and a pre-set plan. On February 2, 2026, he sold 21,582, 25,375, and 20,701 shares of common stock, each at $1.39 per share.
The filing states one sale was made under a Rule 10b5-1 trading plan adopted on November 17, 2023, and the other two were automatic sales by Akebia to cover tax withholding obligations upon vesting of restricted stock units granted in 2023, 2024, and 2025. After these transactions, Burke directly beneficially owned 948,432 shares of Akebia common stock.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported multiple automatic stock sales tied to equity compensation. On February 2, 2026, she sold 16,846, 25,382, and 27,544 shares of Akebia common stock at $1.39 per share in separate transactions.
The filing states one sale was made under a Rule 10b5-1 trading plan adopted on September 8, 2025. The other sales were made automatically by Akebia to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on January 31, 2023, January 31, 2024, and January 31, 2025. After these transactions, Rucci directly beneficially owned 588,378 shares of common stock.
Akebia Therapeutics, Inc. executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer, reported a sale of common stock. On February 2, 2026, he sold 34,951 shares at $1.39 per share.
According to the filing, the sale was made automatically by Akebia to cover tax withholding obligations tied to the vesting and settlement of one-third of his restricted stock units granted on January 31, 2025. The transaction was carried out under a Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owns 672,635 shares of Akebia common stock directly.
Akebia Therapeutics CEO and President John P. Butler, who is also a director, reported several transactions in Akebia common stock on February 2, 2026. He sold 46,660, 96,065, 114,891, and 83,689 shares at $1.39 per share. According to the footnotes, most of these sales were made automatically by the company to cover tax withholding when restricted stock units and performance stock units vested, and were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025. Butler also acquired 175,250 shares at $1.41 per share upon vesting of performance-based restricted stock units after a stock price performance condition was certified and met. Following these transactions, he directly held 3,297,794 shares and indirectly held 159,928 shares through the Dorothy Butler Revocable Trust dated November 20, 2007.
Akebia Therapeutics’ Chief Commercial Officer Nicholas Grund received new equity awards, aligning his compensation with company performance. On January 30, 2026, he was granted 204,000 shares of common stock as restricted stock units at $0.00 per share, bringing his directly owned common stock to 646,579 shares.
He was also granted a stock option for 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. The RSUs vest in three equal annual installments, while the options vest over four years, both subject to his continued service.
Akebia Therapeutics disclosed that SVP and Chief Medical Officer Steven K. Burke received new equity awards on January 30, 2026. He was granted 204,000 restricted stock units of common stock at no cost and 320,000 stock options with a $1.41 exercise price.
The 204,000 restricted stock units vest in three equal installments on the first, second, and third anniversaries of the grant date, conditioned on continued service. The 320,000 options vest over four years, with 25% after one year and the remaining 75% in equal quarterly installments. Following the grant, Burke directly beneficially owns 1,016,090 shares of common stock, including 3,000 shares acquired through the company’s employee stock purchase plan.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported new equity awards. On January 30, 2026, she received 190,000 shares of common stock in the form of restricted stock units at $0.00 per share, bringing her directly held common stock to 658,150 shares.
She was also granted a stock option for 270,000 shares of common stock with a $1.41 exercise price, all held directly. The restricted stock units vest in three equal annual installments, while the options vest over four years, both subject to continued service with the company.
Akebia Therapeutics reported an equity grant to SVP and Chief Accounting Officer Richard C. Malabre. On January 30, 2026, he received 79,000 restricted stock units and 119,000 stock options with a $1.41 exercise price, issued under Akebia’s 2023 Stock Incentive Plan.
The restricted stock units vest in three equal annual installments on the first, second and third anniversaries of the grant date, assuming continued service. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal quarterly installments. After this grant, Malabre beneficially owns 348,914 shares of common stock, including shares bought through the company’s employee stock purchase plan, and holds 119,000 stock options.
Akebia Therapeutics reported an equity compensation grant to its senior executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer. On January 30, 2026, he received 204,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 707,586 shares.
He was also granted stock options covering 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. One third of the restricted stock units vest on each of the first three anniversaries of the grant date, while 25% of the options vest on the first anniversary and the remaining 75% vest in equal quarterly installments over the following three years, in each case contingent on continued service.
Akebia Therapeutics CEO and President John P. Butler reported new equity awards on January 30, 2026. He received 743,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 3,463,849 shares.
He was also granted a stock option for 1,115,000 shares at an exercise price of $1.41 per share, expiring on 01/30/2036. These options vest over four years, while the restricted stock units vest in three equal annual installments, both subject to his continued service. An additional 159,928 shares are held indirectly through the Dorothy Butler Revocable Trust.